OXNARD, Calif., March 16, 2017 -- CURE Pharmaceutical (OTCQB:CURR), (“CURE”) or (the “company”), a leading disruptive drug delivery technology company serving the pharmaceutical, biotech, veterinarian, nutraceutical and medical foods markets, and developing cannabinoid molecules and new chemical entities (NCEs), today announces it will be an exhibitor at the INTERPHEX 2017 conference on March 21-23 at the Javits Center, 655 W34th Street, New York City. During the conference, the company can be found at Booth #1563.
“INTERPHEX is a nationally recognized conference where top manufacturers and drug development professionals discuss the newest techniques and trends in the industry,” said Wayne Nasby, COO of CURE Pharmaceutical. “The INTERPHEX conference is an integral part of our strategy to identify potential partnerships within the pharmaceutical industry, capitalizing on opportunities to demonstrate our proprietary drug delivery technology and manufacturing capabilities to industry leaders.”
About CURE Pharmaceutical
Headquartered in Oxnard, CA, CURE Pharmaceutical is a fully integrated specialty pharmaceutical/bioscience company with disruptive proprietary drug delivery technologies for a broad range of molecules that it develops and manufactures in its state of the art cGMP facility. CURE leverages novel drug delivery technologies to develop and commercialize new applications of proven therapeutics. Cure partners with pharmaceutical and biotech companies looking for new methods to deliver their proprietary molecules. The technology enables differentiation within large therapeutic categories and potentially improves patient compliance while widening the therapeutic index. CURE Pharmaceutical is traded under the symbol CURR. For more information about CURE Pharmaceutical, please visit its website at www.curepharmaceutical.com.
About INTERPHEX
For the past 38 years, INTERPHEX has been, and continues to be, the premier pharmaceutical, biotechnology, and device development and manufacturing event where you can “Experience Science through Commercialization.” Sponsored by the Parenteral Drug Association (PDA), the event is based in New York and brings over 11,500 global industry professionals and 625+ industry leading suppliers together to “Learn it, Experience it, Procure it” through a unique combination of no cost technical conference, exhibits, demonstrations, workshops, partnering opportunities and networking to leverage quality, efficiency and cost effectiveness in today’s ever-changing global market. INTERPHEX offers annual domestic and international industry events and educational opportunities around the world. Follow INTERPHEX on Facebook, LinkedIn, Instagram, YouTube, and Twitter. IPX Blog continues the learning beyond the show floor. For more information, visit www.INTERPHEX.com.
Forward-looking statements
This press release contains forward-looking statements, which are subject to a number of risks and uncertainties. All statements, other than statements of fact, including those statements with respect to the Company's business development, are forward-looking statements. Forward-looking statements speak only as of the date made and are not guarantees of future performance. We undertake no obligation to publicly update or revise any forward-looking statements.
Contact: Jules Abraham JQA Partners, Inc. 917-885-7378 [email protected]


SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
Instagram Outage Disrupts Thousands of U.S. Users
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile
Ford and Geely Explore Strategic Manufacturing Partnership in Europe
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate 



